916211-79-5

Basic information

• Product Name: 3-Chloro-1H-pyrazol-5-aMine
• Synonyms: 3-Chloro-1H-pyrazol-5-aMine;5-chloro-1H-pyrazol-3-aMine;EOS-61385
• CAS NO: 916211-79-5
• Molecular Formula: C₃H₄ClN₃
• Molecular Weight: 117.53696
• Mol File: 916211-79-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 394.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.562±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.32±0.10(Predicted)
• CAS DataBase Reference: 3-Chloro-1H-pyrazol-5-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-1H-pyrazol-5-aMine(916211-79-5)
• EPA Substance Registry System: 3-Chloro-1H-pyrazol-5-aMine(916211-79-5)

Safety Data

• Hazardous Substances Data: 916211-79-5(Hazardous Substances Data)

Usage

General Description

3-chloro-1H-pyrazol-5-amine, also known as 3-chloro-5-aminopyrazole, is a chemical compound with the molecular formula C3H5ClN4. It is a chlorinated derivative of pyrazol-5-amine and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drug molecules. This chemical is a white to off-white crystalline powder with a melting point of 219-221°C and has a molecular weight of 136.55 g/mol. It is a versatile intermediate that is used in the production of a wide range of pharmaceuticals and agrochemicals. In addition, 3-chloro-1H-pyrazol-5-amine possesses potential biological activities and can be used in the development of new drugs. It is important to handle this compound with care and follow proper safety protocols as it may have hazardous properties.

Upstream product

• 1369959-12-5 3-chloro-5-nitro-1H-pyrazole 
• 28491-52-3 5-amino-1,2-dihydropyrazol-3-one 

Downstream Products

• 1369958-92-8 C₂₄H₂₁Cl₃FN₅O 

Relevant articles and documents

COMPOUNDS FOR MALT1 DEGRADATION

Provided herein are bifunctional compounds that inhibit MALTl and/or promote targeted ubiquitination for the degradation of MALTl. In particular, provided are compounds that can bind MALTl, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALTl, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALTl, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.